Clinical significance and efficacy analysis of atorvastatin in the treatment of patients with cerebral infarction and aspiration pneumonia

Wei,Bing; Liu,Yugeng

doi:10.3892/etm.2018.6829

Clinical significance and efficacy analysis of atorvastatin in the treatment of patients with cerebral infarction and aspiration pneumonia

Authors:
- Bing Wei
- Yugeng Liu
View Affiliations

Affiliations: Department of Emergency Medicine, Beijing Chaoyang Hospital Jingxi Branch, Capital Medical University, Beijing 100043, P.R. China
Published online on: October 4, 2018 https://doi.org/10.3892/etm.2018.6829
Pages: 5144-5148
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Therapeutic efficacy of the use of oral atorvastatin in the treatment of patients with aspiration pneumonia complicated with cerebral infarction was investigated. Three hundred and fourteen cerebral infarction patients complicated with aspiration pneumonia who were admitted to the emergency department of Beijing Chaoyang Hospital Jingxi Branch from May 2015 to July 2017 were retrospectively analyzed. Among them, 160 patients who took atorvastatin were treated as observation group, and the remaining 154 patients were the control group. Patients were given basic treatment after diagnosis, and atorvastatin was also used for patients in the observation group. Venous blood was extracted to detect blood lipids and inflammatory cytokines. Patients were followed up for a period of six months, and the mortality was recorded. After treatment, blood lipid function and inflammatory factors in both groups were significantly improved (P<0.05). Hospital stay in the observation group (86.88%) was significantly shorter than that in the control group (76.33%) (P<0.01). After treatment, levels of TC, LDL, TG and CRP in the observation group (86.25%) were significantly lower than those in the control group (76.32%) (P=0.01). However, after treatment, level of HDL-C in the observation group (11.88%) was significantly higher than that in the control group (23.38%) (P=0.01). After treatment, levels of IL-6, IL-8 and TNF-α in the observation group were significantly lower than those in the control group (P<0.01). Total effective rate in the observation group was significantly higher than that of the control group (P=0.01). Total death rate in the observation group was significantly lower than that in the control group (P=0.02). In conclusion, atorvastatin is effective in the treatment of cerebral infarction patients complicated with aspiration pneumonia.

View Figures

View References

1	Tan XL, Xue YQ, Ma T, Wang X, Li JJ, Lan L, Malik KU, McDonald MP, Dopico AM and Liao FF: Partial eNOS deficiency causes spontaneous thrombotic cerebral infarction, amyloid angiopathy and cognitive impairment. Mol Neurodegener. 10:242015. View Article : Google Scholar : PubMed/NCBI
2	Zeng Q, Lin K, Yao M and Wei L: Significant correlation between cystatin C, cerebral infarction, and potential biomarker for increased risk of stroke. Curr Neurovasc Res. 12:40–46. 2015. View Article : Google Scholar : PubMed/NCBI
3	Jabbarli R, Reinhard M, Roelz R, Shah M, Niesen WD, Kaier K, Taschner C, Weyerbrock A and Van Velthoven V: Early identification of individuals at high risk for cerebral infarction after aneurysmal subarachnoid hemorrhage: The BEHAVIOR score. J Cereb Blood Flow Metab. 35:1587–1592. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ye H, Wang L, Yang XK, Fan LP, Wang YG and Guo L: Serum S100B levels may be associated with cerebral infarction: A meta-analysis. J Neurol Sci. 348:81–88. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ye L, Cai R, Yang M, Qian J and Hong Z: Reduction of the systemic inflammatory induced by acute cerebral infarction through ultra-early thrombolytic therapy. Exp Ther Med. 10:1493–1498. 2015. View Article : Google Scholar : PubMed/NCBI
6	Jabbarli R, Reinhard M, Niesen WD, Roelz R, Shah M, Kaier K, Hippchen B, Taschner C and Van Velthoven V: Predictors and impact of early cerebral infarction after aneurysmal subarachnoid hemorrhage. Eur J Neurol. 22:941–947. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fu HJ, Zhao LB, Xue JJ, Wu ZX, Huang YP, Liu W and Gao Z: Elevated serum homocysteine (Hcy) levels may contribute to the pathogenesis of cerebral infarction. J Mol Neurosci. 56:553–561. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wu W, Guan Y, Xu K, Fu XJ, Lei XF, Lei LJ, Zhang ZQ, Cheng Y and Li YQ: Plasma homocysteine levels predict the risk of acute cerebral infarction in patients with carotid artery lesions. Mol Neurobiol. 53:2510–2517. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, Patel A and Rebollo-Mesa I; STROKE-INF Investigators, . Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): A prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet. 386:1835–1844. 2015. View Article : Google Scholar : PubMed/NCBI
10	Yang JW and Hu ZP: Neuroprotective effects of atorvastatin against cerebral ischemia/reperfusion injury through the inhibition of endoplasmic reticulum stress. Neural Regen Res. 10:1239–1244. 2015. View Article : Google Scholar : PubMed/NCBI
11	Yang N, Lin M, Wang BG, Zeng WY, He YF, Peng HY, Zeng J, Wu ZY and Zhong Y: Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction. Eur Rev Med Pharmacol Sci. 20:673–678. 2016.PubMed/NCBI
12	Fang X, Tao D, Shen J, Wang Y, Dong X and Ji X: Neuroprotective effects and dynamic expressions of MMP9 and TIMP1 associated with atorvastatin pretreatment in ischemia-reperfusion rats. Neurosci Lett. 603:60–65. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kumar A, Brown R, Dhar R, Sampson T, Derdeyn CP, Moran CJ and Diringer MN: Early vs. delayed cerebral infarction after aneurysm repair after subarachnoid hemorrhage. Neurosurgery. 73:617–623. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chen B, Grothe C and Schaller K: Validation of a new neurological score (FOUR Score) in the assessment of neurosurgical patients with severely impaired consciousness. Acta Neurochir (Wien). 155:2133–2139. 2013. View Article : Google Scholar : PubMed/NCBI
15	Whyte J, Nordenbo AM, Kalmar K, Merges B, Bagiella E, Chang H, Yablon S, Cho S, Hammond F, Khademi A, et al: Medical complications during inpatient rehabilitation among patients with traumatic disorders of consciousness. Arch Phys Med Rehabil. 94:1877–1883. 2013. View Article : Google Scholar : PubMed/NCBI
16	Li RY, Cao ZG, Li Y and Wang RT: Increased whole blood viscosity is associated with silent cerebral infarction. Clin Hemorheol Microcirc. 59:301–307. 2015. View Article : Google Scholar : PubMed/NCBI
17	Koh SH and Lo EH: The role of the PI3K pathway in the regeneration of the damaged brain by neural stem cells after cerebral infarction. J Clin Neurol. 11:297–304. 2015. View Article : Google Scholar : PubMed/NCBI
18	Honeybul S, Ho KM and Gillett G: Outcome following decompressive hemicraniectomy for malignant cerebral infarction: Ethical considerations. Stroke. 46:2695–2698. 2015. View Article : Google Scholar : PubMed/NCBI
19	Du R, Teng JF, Wang Y, Zhao XY and Shi ZB: Clinical study of Butylphthalide combined with Xue Shuan Tong on serum inflammatory factors and prognosis effect of patients with cerebral infarction. Pak J Pharm Sci. 28 Suppl:1823–1827. 2015.PubMed/NCBI
20	Yang N, Lin M, Wang BG, Zeng WY, He YF, Peng HY, Zeng J, Wu ZY and Zhong Y: Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction. Eur Rev Med Pharmacol Sci. 20:673–678. 2016.PubMed/NCBI
21	Kucera M, Balaz D, Kruzliak P, Ciccocioppo R, Oravec S, Rodrigo L, Zulli A, Hirnerova E, Sabaka P, Komornikova A, et al: The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators - A pilot study. Clin Biochem. 48:557–561. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wu W, Guan Y, Xu K, Fu XJ, Lei XF, Lei LJ, Zhang ZQ, Cheng Y and Li YQ: Plasma homocysteine levels predict the risk of acute cerebral infarction in patients with carotid artery lesions. Mol Neurobiol. 53:2510–2517. 2016. View Article : Google Scholar : PubMed/NCBI
23	Zhang J, Mu X, Breker DA, Li Y, Gao Z and Huang Y: Atorvastatin treatment is associated with increased BDNF level and improved functional recovery after atherothrombotic stroke. Int J Neurosci. 127:92–97. 2017. View Article : Google Scholar : PubMed/NCBI
24	Pantan R, Tocharus J, Suksamrarn A and Tocharus C: Synergistic effect of atorvastatin and Cyanidin-3-glucoside on angiotensin II-induced inflammation in vascular smooth muscle cells. Exp Cell Res. 342:104–112. 2016. View Article : Google Scholar : PubMed/NCBI